A Phase 1/2 Study to Evaluate MEDI4736

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in participants with advanced solid tumors followed by an expansion phase in participants with advanced solid tumors. An exploration cohort has been added to determine the safety using every 4 weeks (Q4W) dosing.

Official Title

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

Eligibility Criteria

Ages Eligible for Study: 18 Years to 99 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Age 18 or older. - In the dose-escalation phase: histologically- or cytologically- confirmed advanced solid tumor that is refractory to standard therapy and for which no standard therapy exists. - In the dose-expansion phase: histologically- or cytologically- confirmed advanced solid tumor where if an approved first-line therapy is available, participants must have failed, be intolerant to, be ineligible for, or have refused - Eastern Cooperative Oncology Group (ECOG) status of 0 or 1. - Adequate organ and marrow function. - Participants must have at least 1 measurable lesion. - Available archived tumor tissue sample. - Willingness to provide consent for biopsy sample (dose-expansion only)
Exclusion Criteria:
  1. - Any prior Grade ≥ 3 immune-mediated adverse event (imAE) while receiving immunotherapy - Prior exposure to any anti-PD-1 or anti-PD-L1 antibody - Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. - Prior treatment with immunotherapy agents including, but not limited to, tumor necrosis factor receptor superfamily agonists or checkpoint inhibitors or natural killer (NK) cell inhibitors. - Active or prior documented autoimmune disease within the past 2 years - History of primary immunodeficiency - History of organ transplant that requires use of immunosuppressives - Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment - Other invasive malignancy within 2 years - Women who are pregnant or lactating - Uncontrolled intercurrent illness - Known history of tuberculosis - Known to be human immunodeficiency virus (HIV) positive - Known to be Hepatitis B or C positive (except HCC participants)


Kavitha Ramchandran
Kavitha Ramchandran
Medical oncologist, Palliative medicine doctor, Thoracic specialist, Internal medicine doctor
Clinical Professor, Medicine - Oncology
Millie Das
Millie Das
Medical oncologist, Thoracic specialist
Clinical Associate Professor, Medicine - Oncology
Heather Wakelee
Heather Wakelee
Medical oncologist, Thoracic specialist
Professor of Medicine (Oncology)
Joel Neal, MD, PhD
Joel Neal, MD, PhD
Medical oncologist, Thoracic specialist
Associate Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.


Cancer Clinical Trials Office